Current residents

Pepticom Ltd. founded in 2011, is focused on the discovery of novel peptide-drug candidates. Pepticom’s key asset is a unique Artificial Intelligence platform for peptide design, based on the target's solved crystal structure. Pepticom operates in various markets, generating innovative binding peptides for diverse targets. Past successful discoveries include active molecules in metabolic diseases, Alzheimer's disease and Immunomodulators.

Nectin Therapeutics, established by Integra Holdings in 2017, is dedicated to the development of next generation immuno-oncology antibodies. The company's antibodies are based on the discoveries and inventions of Prof. Ofer Mandelboim from the Hebrew University and Prof. Stipan Jonjic from the University of Rijeka. Integra Holdings & Yissum are the key shareholders.

Omnix Medical founded in 2015, is developing novel antibiotic agents for the treatment of hospital-acquired infections involving drug resistant bacteria. Omnix’s technology is based on natural antimicrobial peptides, biochemically engineered to be compatible for therapeutic applications. Omnix’s lead molecule, OMN6, employs a unique mechanism of action, representing a new antibiotic class, characterized by a rapid-bactericidal effect. OMN6 was found to be active irrespective of resistance to other antibiotic drugs, and thus, offers a safer more efficient alternative to current therapies.

Dr. Moshik Cohen-Kutner  Co-Founder & CEO
Dr. Niv Bachnoff  Co-Founder & CSO
Mr. Rom Lakritz  CPA, Co-Founder & CFO/COO
Ms. Shira Merchavia  Research Director
Ms. Janna Michaeli  Preclinical Director  
Dr. Jonathan Zazun  PharmD, CMC Director 
Ms. Noa Nur Research Scientist
Ms. Esti Rotshtein Operations Manage

Protica Bio was founded in 2022. The company combines cutting-edge proteomics and machine learning to improve immunotherapy-based clinical decisions and new drug discoveries to revolutionize diagnostic prediction and future treatment. The company is utilizing a proprietary platform developed by a leading expert in the field of Mass spectrometry from the Weizmann Institute. In addition to laboratory research, the company integrates deep proteomics with machine learning to create diagnostic capabilities and elevate the response rate for current and future treatments.

DairyX, founded in 2022, is a FoodTech startup that aims to produce animal-free dairy products by producing functional milk proteins in yeast. DairyX seeks to create products that taste and cost like traditional dairy products without the health hazards and hurting animals and using a ~10% of the land, water, and CO2e resources needed for the conventional dairy industry.

Ambrosia Bio ltd. is a biotech company developing an enzyme-based technological platform capable of converting everyday sugars into low- to no-calorie rare sugars (e.g., allulose, and others) and dietary fibers (scFOS) in a cost-effective manner. Ambrosia bio's business model is based on revamping sugar refineries into specialty ingredient production sites.  

Ziv Zwighaft, PhD, MBA, founder and CEO
Avraham Laban, PhD, CTO
Amir Barzilay, Chairman
Yoav Herschkovitz, PhD, IP & Regulation Affairs
Stanislas Baudouin, VP engineering

NucleoTech, founded in 2022, is dedicated to enable better, noninvasive therapeutic solutions to CNS disorders. Through its innovative screening method, NucleoTech develops a set of proprietary carrier molecules that can effectively shuttle various therapeutics across the Blood-Brain Barrier, thus overcoming one of the main hurdles for effective, noninvasive CNS treatments.
 

Uriah Bekenstein, PhD, Co-Founder & CEO
Adi Koplovitz, Co-Founder & COO 
Naftali Cohen, Co-Founder & head of Business 
Tehila Dahan, PhD, R&D Manager 
Beata Toth-Cohen, PhD, Research Adviser